378 related articles for article (PubMed ID: 10527409)
41. Monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa inhibit adhesion of platelets to purified solid-phase von Willebrand factor.
Danton MC; Zaleski A; Nichols WL; Olson JD
J Lab Clin Med; 1994 Aug; 124(2):274-82. PubMed ID: 8051492
[TBL] [Abstract][Full Text] [Related]
42. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
43. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane.
DiMinno G; Silver MJ; Cerbone AM; Riccardi G; Rivellese A; Mancini M; Thiagarajan P
Blood; 1985 Jan; 65(1):156-62. PubMed ID: 2981130
[TBL] [Abstract][Full Text] [Related]
44. Properties of washed human platelets.
Kinlough-Rathbone RL; Mustard JF; Packham MA; Perry DW; Reimers HJ; Cazenave JP
Thromb Haemost; 1977 Apr; 37(2):291-308. PubMed ID: 327607
[TBL] [Abstract][Full Text] [Related]
45. Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.
Lee MY; Verni CC; Herbig BA; Diamond SL
J Thromb Haemost; 2017 Dec; 15(12):2396-2407. PubMed ID: 28981200
[TBL] [Abstract][Full Text] [Related]
46. Aggregation of human and canine platelets: modulation by purine nucleotides.
Soslau G; Arabe L; Parker J; Pelleg A
Thromb Res; 1993 Oct; 72(2):127-37. PubMed ID: 8303650
[TBL] [Abstract][Full Text] [Related]
47. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
Winocour PD; Kinlough-Rathbone RL; Mustard JF
J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
[TBL] [Abstract][Full Text] [Related]
48. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa).
Andrioli G; Minuz P; Solero P; Pincelli S; Ortolani R; Lussignoli S; Bellavite P
Br J Haematol; 2000 Sep; 110(4):911-8. PubMed ID: 11054082
[TBL] [Abstract][Full Text] [Related]
49. Characterization of an antiglycoprotein Ib monoclonal antibody that specifically inhibits platelet-thrombin interaction.
Mazurov AV; Vinogradov DV; Vlasik TN; Repin VS; Booth WJ; Berndt MC
Thromb Res; 1991 Jun; 62(6):673-84. PubMed ID: 1718052
[TBL] [Abstract][Full Text] [Related]
50. A murine antiglycoprotein Ib complex monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen.
Ruan CG; Du XP; Xi XD; Castaldi PA; Berndt MC
Blood; 1987 Feb; 69(2):570-7. PubMed ID: 3801672
[TBL] [Abstract][Full Text] [Related]
51. Influence of heat on platelet biochemistry, structure, and function.
Rao GH; Smith CM; Escolar G; White JG
J Lab Clin Med; 1993 Oct; 122(4):455-64. PubMed ID: 8228561
[TBL] [Abstract][Full Text] [Related]
52. Aggregated-disaggregated, refractory platelets retain sensitivity to ristocetin.
White JG; Rao GH
Thromb Res; 1996 Nov; 84(4):253-66. PubMed ID: 8948050
[TBL] [Abstract][Full Text] [Related]
53. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
55. Effects of sodium periodate on platelet functions.
Cazenave JP; Reimers HJ; Kinlough-Rathbone RL; Packham MA; Mustard JF
Lab Invest; 1976 May; 34(5):471-81. PubMed ID: 178961
[TBL] [Abstract][Full Text] [Related]
56. Different effects of endothelin-3 on the Ca2+ discharge induced by agonists and Ca(2+)-ATPase inhibitors in human platelets.
Astarie-Dequeker C; Korichneva I; Devynck MA
Br J Pharmacol; 1995 Jan; 114(2):524-30. PubMed ID: 7881751
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo functions of thrombin-treated platelets.
Reimers HJ; Kinlough-Rathbone RL; Cazenave JP; Senyi AF; Hirsh J; Packham MA; Mustard JF
Thromb Haemost; 1976 Feb; 35(1):151-66. PubMed ID: 785686
[TBL] [Abstract][Full Text] [Related]
58. YD-3, a novel inhibitor of protease-induced platelet activation.
Wu CC; Huang SW; Hwang TL; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 2000 Jul; 130(6):1289-96. PubMed ID: 10903968
[TBL] [Abstract][Full Text] [Related]
59. Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
Carroll RC; Wang XF; Lanza F; Steiner B; Kouns WC
Thromb Res; 1997 Oct; 88(2):109-25. PubMed ID: 9361365
[TBL] [Abstract][Full Text] [Related]
60. Influence of vortex speed on fresh versus stored platelet aggregation in the absence and presence of extracellular ATP.
Soslau G; Schechner AJ; Alcasid PJ; Class R
Thromb Res; 2000 Jan; 97(2):15-27. PubMed ID: 10688331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
